Neurotensin receptor 1 determines the outcome of non-small cell lung cancer

Clinical Cancer Research

Volumn 16, Issue 17, 2010, Pages 4401-4410

  Alifano, Marco ^a   Souazé, Frédérique ^c   Dupouy, Sandra ^b   Camilleri Broët, Sophie ^d   Younes, Mohamad ^b   Ahmed Zaïd, Sadi Menad ^b   Takahashi, Takashi ^e   Cancellieri, Alessandra ^f   Damiani, Stefania ^f   Boaron, Maurizio ^f   Broët, Philippe ^d   Miller, Lance D ^g   Gespach, Christian ^b   Regnard, Jean François ^a   Forgez, Patricia ^b  

^a HÔTEL DIEU   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f BELLARIA HOSPITAL   (Italy)

^g WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; NEUROPEPTIDE RECEPTOR; NEUROTENSIN; NEUROTENSIN RECEPTOR 1; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOCRINE EFFECT; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; NUDE MOUSE; OVERALL SURVIVAL; PARACRINE SIGNALING; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

EID: 77956236603     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0659     Document Type: Article

References (33)

1. Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines. Chest 2007;132:29-55S.
2. Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005;97:1407-27.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
4. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-14.
5. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest 1997;111:1718-23.
6. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-7.
7. Broet P, Camilleri-Broet S, Zhang S, et al. Prediction of clinical outcome in multiple lung cancer cohorts by integrative genomics: implications for chemotherapy selection. Cancer Res 2009;69:1055-62.
8. Reinecke M. Neurotensin. Immunohistochemical localization in central and peripheral nervous system and in endocrine cells and its functional role as neurotransmitter and endocrine hormone. Prog Histochem Cytochem 1985;16:1-172.
9. Baca I, Feurle GE, Schwab A, Mittmann U, Knauf W, Lehnert T. Effect of neurotensin on exocrine pancreatic secretion in dogs. Digestion 1982;23:174-83.
10. Andersson S, Rosell S, Hjelmquist U, Chang D, Folkers K. Inhibition of gastric and intestinal motor activity in dogs by (Gln4) neurotensin. Acta Physiol Scand 1977;100:231-5.
11. Zhao D, Pothoulakis C. Rho GTPases as therapeutic targets for the treatment of inflammatory diseases. Expert Opin Ther Targets 2003;7:583-92.
12. Leyton J, Garcia-Marin L, Jensen RT, Moody TW. Neurotensin causes tyrosine phosphorylation of focal adhesion kinase in lung cancer cells. Eur J Pharmacol 2002;442:179-86.
13. Ehlers RA, Zhang Y, Hellmich MR, Evers BM. Neurotensin-mediated activation of MAPK pathways and AP-1 binding in the human pancreatic cancer cell line, MIA PaCa-2. Biochem Biophys Res Commun 2000;269:704-8.
14. Moody TW, Chiles J, Casibang M, Moody E, Chan D, Davis TP. SR48692 is a neurotensin receptor antagonist which inhibits the growth of small cell lung cancer cells. Peptides 2001;22:109-15.
15. Souaze F, Viardot-Foucault V, Roullet N, et al. Neurotensin receptor 1 gene activation by the Tcf/β-catenin pathway is an early event in human colonic adenomas. Carcinogenesis 2006;27:708-16.
16. Maoret JJ, Anini Y, Rouyer-Fessard C, Gully D, Laburthe M. Neurotensin and a non-peptide neurotensin receptor antagonist control human colon cancer cell growth in cell culture and in cells xenografted into nude mice. Int J Cancer 1999;80:448-54.
17. Toy-Miou-Leong M, Cortes CL, Beaudet A, Rostene W, Forgez P. Receptor trafficking via the perinuclear recycling compartment accompanied by cell division is necessary for permanent neurotensin cell sensitization and leads to chronic mitogen-activated protein kinase activation. J Biol Chem 2004;279:12636-46.
18. Najimi M, Souaze F, Mendez M, et al. Activation of receptor gene transcription is required tomaintain cell sensitization after agonist exposure. Study on neurotensin receptor. J Biol Chem 1998;273:21634-41.
19. Somai S, Gompel A, Rostene W, Forgez P. Neurotensin counteracts apoptosis in breast cancer cells. Biochem Biophys Res Commun 2002;295:482-8.
20. Souaze F, Dupouy S, Viardot-Foucault V, et al. Expression of neurotensin and NT1 receptor in human breast cancer: a potential role in tumor progression. Cancer Res 2006;66:6243-9.
21. Shimizu S, Tsukada J, Sugimoto T, et al. Identification of a novel therapeutic target for head and neck squamous cell carcinomas: a role for the neurotensin-neurotensin receptor 1 oncogenic signaling pathway. Int J Cancer 2008;123:1816-23.
22. Dupouy S, Viardot-Foucault V, Alifano M, et al. The neurotensin receptor-1 pathway contributes to human ductal breast cancer progression. PLoS ONE 2009;4:e4223.
23. Kozaki K, Miyaishi O, Tsukamoto T, et al. Establishment and characterization of a human lung cancer cell line NCI-H460-LNM35 with consistent lymphogenous metastasis via both subcutaneous and orthotopic propagation. Cancer Res 2000;60:2535-40.
24. Souaze F, Rostene W, Forgez P. Neurotensin agonist induces differential regulation of neurotensin receptor mRNA. Identification of distinct transcriptional and post-transcriptional mechanisms. J Biol Chem 1997;272:10087-94.
25. Scarceriaux V, Pelaprat D, Forgez P, Lhiaubet AM, Rostene W. Effects of dexamethasone and forskolin on neurotensin production in rat hypothalamic cultures. Endocrinology 1995;136:2554-60.
26. Maoret JJ, Pospai D, Rouyer-Fessard C, et al. Neurotensin receptor and its mRNA are expressed in many human colon cancer cell lines but not in normal colonic epithelium: binding studies and RT-PCR experiments. Biochem Biophys Res Commun 1994;203:465-71.
27. Nguyen DX, Chiang AC, Zhang XH, et al. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 2009;138:51-62.
28. Koon HW, Kim YS, Xu H, et al. Neurotensin induces IL-6 secretion in mouse preadipocytes and adipose tissues during 2,4,6,-trinitrobenzensulphonic acid-induced colitis. Proc Natl Acad Sci U S A 2009;106:8766-71.
29. Zhao D, Zhan Y, Zeng H, Koon HW, Moyer MP, Pothoulakis C. Neurotensin stimulates interleukin-8 expression through modulation of I κ B α phosphorylation and p65 transcriptional activity: involvement of protein kinase C α. Mol Pharmacol 2005;67:2025-31.
30. Wakelee HA, Schiller JH, Gandara DR. Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: implications for the New Intergroup Trial. Clin Lung Cancer 2006;8:18-21.
31. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999;91:1194-210.
32. Rubins J, Unger M, Colice GL. Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline. Chest 2007;132:355-67S.
33. Lu Y, Lemon W, Liu PY, et al. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med 2006;3:e467.